In 2017, the National Academies of Sciences, Engineering, and Medicine published a report showing promising but inconclusive evidence suggesting that interventions like cognitive training, blood pressure control and increased physical activity reduce a person’s risk for dementia, but what does the research show now? Dr. Luke Stoeckel from the National Institute on Aging (NIA) joins the podcast to share where the research on lifestyle interventions is at, why studies on these interventions are difficult to complete and more.
Guest: Luke Stoeckel, PhD, program director, Mechanistic and Translational Decision Science Program, Division of Behavioral and Social Research (DBSR), NIA
Show NotesLearn about the National Academies of Sciences, Engineering, and Medicine on their website.
Read the 2017 National Academies’ report, “Preventing Cognitive Decline and Dementia,” for free on their website.
Learn about the National Academies’ Research Priorities for Preventing and Treating Alzheimer’s Disease and Related Dementias and find upcoming workshops on their website.
Find information on the 2021 National Academies workshop mentioned by Dr. Chin at 1:36 on the National Academies website.
Learn more about Dr. Stoeckel in his bio on the National Institute on Aging website.
Connect with UsFind transcripts and more at our website.
Email Dementia Matters: dementiamatters@medicine.wisc.edu
Follow us on Facebook and Twitter.
Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.
Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer’s. All donations go toward outreach and production.
Promises to Practice: Creating Sustainable Community Partnerships to Support Alzheimer’s Research
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
Deciding to Donate: Barriers and Benefits of Brain Donations for Diverse Populations
Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness
Understanding the Social Determinants of Health and Disparities in Alzheimer’s Research
Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging
The National Strategy for Diversifying Alzheimer’s Research
The Future of Neuroscience: Early-Career Researchers Named ’One to Watch’ by the Alzheimer’s Association
Studies Look at Generational Differences and Associations between Cognition, Sensory Changes and Blood Biomarkers
Disclosing Alzheimer’s Disease Biomarker Results in Diverse Populations
Difficult but Beneficial Conversations about End-of-Life Care
Caregiving While Black: Dementia Care for Different Racial and Ethnic Groups
Our Evolving Understanding of Mild Cognitive Impairment
A Closer Look at the Lecanemab Clinical Trials
Therapeutic Fibbing: Mastering the Art of Communicating with a Loved One with Dementia
The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease
Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks